OBJECTIVE: To systematically evaluate the improvement effect and safety of agomelatine in patients with depression and sleep disorders based on the Meta-analysis method

so as to provide evidence-based reference for clinical treatment.METHODS: PubMed

the Cochrane Library

EMBase

CNKI

Wanfang database and VIP database were retrieved to collect the Chinese and English literature of agomelatine in the treatment of patients with depression and sleep disorders published from the establishment of the database to Apr. 2020. The study group was treated with agomelatine alone

while the control group received serotonin reuptake inhibitor antidepressants（ mirtazapine

paroxetine or escitalopram） alone or agomelatine in combination with other medications. Hamilton Depression Scale（ HAMD） score and Pittsburgh Sleep Quality Index（ PSQI） were extracted

and RevMan 5. 3 software was used for literature quality evaluation and Meta-analysis. RESULTS: Totally 8 literature were collected

including 332 patients.Meta-analysis results showed that the HAMD score（ SMD =-5. 31

95% CI =-6. 28--4. 33

P < 0. 000 01） and PSQI total score（ SMD =-3. 66

95%CI =-4. 16--3. 17

P <0. 000 01） of patients with depression and sleep disorders with treatment of agomelatine alone were significantly lower than those before treatment

with statistically significant difference. CONCLUSIONS: The improvement of agomelatine in patients with depression and sleep disorders is significant.However

due to the limitation of the quality and sample size of the included studies

the conclusion needs to be verified by the results of large sample

multi-center and long-term follow-up.